PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Pharmacists voice concerns over Brexit medicine supplies

A new survey, published by Medicspot, has revealed that pharmacists are “worried” about the supply of medicines to the UK, after we officially left the European Union (EU) on 31 January.

The study demonstrated that eight in 10 pharmacists (84%) in the UK believe their pharmacy will be impacted by the UK’s departure from the EU, with 79% saying they feel fearful about the changes on the horizon.

Further, almost nine in 10 pharmacists (87%) are concerned about the supply of medicines after Brexit and four in 10 pharmacists (42%) have even considered stockpiling drugs in preparation.

It also revealed that almost four in 10 (39%) predict their team will shrink after the UK’s departure from the EU, with only 6% believing their team will grow.

As the Brexit deadline passed, the government revealed over 200 medicine products faced supply issues in 2019, including ten medicines that faced stock issues for at least ten months.

As such, it “is important that there continues to be an effective movement of medicines and medical devices across borders with the European Union. To this end, we continue to be in close contact with Government and regulators about preparations for Brexit,” commented Mark Lyonette, chief executive officer of the National Pharmacy Association (NPA), who supported the survey.

He continued, “Medicine prices, licensing of medicinal products, safety protocols and health sector workforce will all be impacted by the UK’s departure from the EU. Timely supply of medicines is important to patient wellbeing, so maintaining a safe and effective medicine supply service continues to be our primary focus.”

The findings were part of a wider ‘State of Pharmacy’ report published by Medicspot and supported by the NPA, exploring the pressing issues facing pharmacy today.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026